Document Detail


Pitavastatin reduces elevated IL-18 levels in Japanese subjects with hypercholesterolemia: sub-analysis of Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN).
MedLine Citation:
PMID:  20940516     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Pitavastatin significantly improved lipid profiles and reduced serum high-sensitivity C-reactive protein (hs-CRP) levels in a multi-center and prospective study. The aim of this study was to explore the effect of pitavastatin on serum levels of another inflammatory biomarker, interleukin-18 (IL-18), in a sub-analysis of the previous multi-center prospective study.
METHODS: The subjects were 83 patients derived from the KISHIMEN study. Pitavastatin (1-2 mg/day) was administered for 12 months. Serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), remnant-like particle cholesterol (RLP-C), triglycerides (TG), IL-18, and high sensitivity C-reactive protein (hs-CRP) levels were measured.
RESULTS: TC, LDL-C, and RLP-C levels were significantly reduced by 18.3%, 30.1%, and 21.0% (mean values) at 12 months after pitavastatin administration. TG levels were decreased by 9.8% in subjects whose basal TG levels were above 150 mg/dL. HDL-C levels were significantly increased at 6 months (11.9%). Pitavastatin did not significantly alter IL-18 levels in overall subjects, but reduced IL-18 levels in the highest quartile by 24.5% (median value) at 12 months. Pitavastatin significantly reduced hs-CRP levels by 28.6% in overall subjects and by 62.4% in the highest quartile at 12 months. There was a significant correlation between IL-18 and hs-CRP at baseline after both values were transformed into logarithms (Pearson's correlation coefficient, r = 0.259, p = 0.0181); however, percent changes in these levels were not significantly correlated.
CONCLUSION: Pitavastatin significantly improves lipid profiles, and reduces enhanced inflammation monitored by IL-18, as well as by hs-CRP, in hypercholesterolemic subjects.
Authors:
Yoshio Fujioka; Akira Fukuda; Tatsuro Ishida; Shinji Kagimoto; Yoshio Nakamura; Akane Iwakura; Kyoko Hara; Taizo Yamamoto; Akira Kuroe; Michihiro Ohya; Shinpei Fujimoto; Yoshiyuki Hamamoto; Sachiko Honjo; Hiroki Ikeda; Koichiro Nabe; Kinsuke Tsuda; Ataru Taniguchi; Kiyoshi Tanaka; Hiroyuki Koshiyama; Noriaki Kume; Ken-ichi Hirata
Related Documents :
8421086 - Differences in postprandial lipemia between patients with normal glucose tolerance and ...
165366 - Human plasma triglyceride labeling after high sucrose feeding. ii. study on triglycerid...
19763016 - Measurement performance of reagent manufacturers by centers for disease control and pre...
10085766 - Studies on equine lipid metabolism. 2. lipolytic activities of plasma and tissue lipase...
16424266 - Evidence of a dietary selection for methionine by the piglet.
3986016 - Effects of estradiol and progesterone on the increased synthesis of collagen in atheros...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study     Date:  2010-10-06
Journal Detail:
Title:  Journal of atherosclerosis and thrombosis     Volume:  18     ISSN:  1880-3873     ISO Abbreviation:  J. Atheroscler. Thromb.     Publication Date:  2011  
Date Detail:
Created Date:  2011-02-01     Completed Date:  2011-05-31     Revised Date:  2011-08-16    
Medline Journal Info:
Nlm Unique ID:  9506298     Medline TA:  J Atheroscler Thromb     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  8-15     Citation Subset:  IM    
Affiliation:
Division of Clinical Nutrition, Faculty of Nutrition, Kobe Gakuin University, Kobe, Japan. fujioka@nutr.kobegakuin.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / blood,  drug therapy*
Interleukin-18 / blood*
Japan
Male
Middle Aged
Prospective Studies
Quinolines / therapeutic use*
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Interleukin-18; 0/Quinolines; 147511-69-1/pitavastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  K469E polymorphism of the intercellular adhesion molecule-1 gene in Egyptians with coronary heart di...
Next Document:  HSG/Mfn2 gene polymorphism and essential hypertension: a case-control association study in Chinese.